Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 2536 in metastatic hormone-refractory prostate cancer (single-arm phase II)
2005-005255-18Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BI-2536 in prostate cancer (PCa), sponsored by Boehringer Ingelheim. Primary endpoint: PSA response rate according to PSAWG criteria at 12 weeks. Started Mar 2006; status: completed.
02
Drugs
BI-2536
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005255-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005255-18.